15-PGDH inhibition activates the splenic niche to promote hematopoietic regeneration

Julianne N.P. Smith, … , Sanford D. Markowitz, Amar B. Desai


The splenic microenvironment regulates hematopoietic stem and progenitor cell (HSPC) function, particularly during demand-adapted hematopoiesis, however practical strategies to enhance splenic support of transplanted HSPCs have proven elusive. We have previously demonstrated that inhibiting 15-hydroxyprostaglandin dehydrogenase (15-PGDH), using the small molecule (+)SW033291 (PGDHi), increases bone marrow (BM) prostaglandin E2 (PGE2) levels, expands HSPC numbers, and accelerates hematologic reconstitution following BM transplantation (BMT) in mice. Here we demonstrate that the splenic microenvironment, specifically 15-PGDH high-expressing macrophages (MΦs), megakaryocytes (MKs), and mast cells (MCs), regulates steady-state hematopoiesis and potentiates recovery after BMT. Notably, PGDHi-induced neutrophil, platelet, and HSPC recovery were highly attenuated in splenectomized mice. PGDHi induced non-pathologic splenic extramedullary hematopoiesis at steady-state, and pre-transplant PGDHi enhanced the homing of transplanted cells to the spleen. 15-PGDH enzymatic activity localized specifically to MΦs, MK lineage cells, and MCs, identifying these cell types as likely coordinating the impact of PGDHi on splenic HSPCs. These findings suggest that 15-PGDH expression marks novel HSC niche cell types that regulate hematopoietic regeneration. Therefore, PGDHi provides a well-tolerated strategy to therapeutically target multiple HSC niches and to promote hematopoietic regeneration and improve clinical outcomes of BMT.

Find the latest version:
https://jci.me/143658/pdf
15-PGDH Inhibition Activates the Splenic Niche to Promote Hematopoietic Regeneration

Julianne N.P. Smith¹, Dawn M. Dawson¹, Kelsey F. Christo¹, Alvin P. Jogasuria¹, Mark J. Cameron¹, Monika I. Antczak³, Joseph M. Ready³,⁴, Stanton L. Gerson¹,², Sanford D. Markowitz¹,², Amar B. Desai¹

¹Department of Medicine, and Case Comprehensive Cancer Center Case Western Reserve University, Cleveland OH 44106 USA
²University Hospitals Seidman Cancer Center, Cleveland OH 44106 US
³Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas TX 75390 USA
⁴Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas TX 75390 USA

*Correspondence:
Amar B. Desai
Department of Medicine
Case Western Reserve University
Abd10@case.edu
216-368-6739

Running title: Splenic Activation for Hematologic Regeneration

Total word count: 7,398
Abstract word count: 188
Figures: 7
Tables: 1
References: 53

Conflict of Interest Disclosures:
The authors (A. Desai, J.M. Ready, S.L. Gerson, and S.D. Markowitz) hold patents relating to use of 15-PGDH inhibitors in bone marrow transplantation (US Patents: CA2870666A1 and CA2927730A1) that have been licensed to Rodeo Therapeutics. Drs. Markowitz, Gerson, and Ready are founders of Rodeo Therapeutics, and Drs. Markowitz, Gerson, Ready, and Desai are consultants to Rodeo Therapeutics. Conflicts of interest are managed according to institutional guidelines and oversight by Case Western Reserve University and the University of Texas at Southwestern. No conflict of interest pertains to any of the remaining authors.
Abstract

The splenic microenvironment regulates hematopoietic stem and progenitor cell (HSPC) function, particularly during demand-adapted hematopoiesis, however practical strategies to enhance splenic support of transplanted HSPCs have proven elusive. We have previously demonstrated that inhibiting 15-hydroxyprostaglandin dehydrogenase (15-PGDH), using the small molecule (+)SW033291 (PGDHi), increases bone marrow (BM) prostaglandin E2 (PGE2) levels, expands HSPC numbers, and accelerates hematologic reconstitution following BM transplantation (BMT) in mice. Here we demonstrate that the splenic microenvironment, specifically 15-PGDH high-expressing macrophages (MΦs), megakaryocytes (MKs), and mast cells (MCs), regulates steady-state hematopoiesis and potentiates recovery after BMT. Notably, PGDHi-induced neutrophil, platelet, and HSPC recovery were highly attenuated in splenectomized mice. PGDHi induced non-pathologic splenic extramedullary hematopoiesis at steady-state, and pre-transplant PGDHi enhanced the homing of transplanted cells to the spleen. 15-PGDH enzymatic activity localized specifically to MΦs, MK lineage cells, and MCs, identifying these cell types as likely coordinating the impact of PGDHi on splenic HSPCs. These findings suggest that 15-PGDH expression marks novel HSC niche cell types that regulate hematopoietic regeneration. Therefore, PGDHi provides a well-tolerated strategy to therapeutically target multiple HSC niches and to promote hematopoietic regeneration and improve clinical outcomes of BMT.
Introduction

The spleen influences hematopoietic stem cell transplantation outcomes, yet the mechanisms regulating splenic hematopoiesis post-transplantation are not well-understood. In mice, transplanted hematopoietic stem and progenitor cells (HSPCs) home to the spleen prior to the bone marrow (BM) (1) and spleen-homed HSPCs demonstrate superior function relative to BM-homed HSPCs several hours post-transplant (2). In the days to weeks following transplantation, hematopoietic foci form in the spleen (3, 4), corresponding to sites of HSPC proliferation and maturation. In humans, splenomegaly portends delayed neutrophil and platelet engraftment (5), however, splenectomy does not improve survival and has been linked to graft versus host disease and lymphoproliferative disease (6, 7). Thus the spleen is capable of both positively and negatively regulating hematopoietic reconstitution and further investigation into the interactions between the splenic microenvironment and transplanted HSPCs is necessary.

HSPCs lodge in the spleen via CXCL12 expressed by peri-sinusoidal cells in the red pulp (8). In the setting of splenic extramedullary hematopoiesis (EMH), CXCL12+ and SCF+ stromal cell populations also promote HSPC activation and myelo-erythroid progenitor cell expansion (9), while VCAM1+ macrophages retain HSPCs in the spleen (10). These findings highlight the potential therapeutic utility of strategies to promote or limit EMH, to improve hematopoietic regeneration or limit inflammation mediated by spleen-derived myeloid cells, as occurs in cardio- and neuro-vascular disease (4, 11, 12).

We have previously shown that inhibition of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) expands HSPCs at steady-state, and enhances hematopoietic regeneration following transplantation and during BM failure (13-15). 15-PGDH inhibition (PGDHi) increases PGE2 and induces Cxcl12 and Scf expression by BM stromal cells, however the impact of PGDHi on the spleen, particularly post-transplant, is not well-understood. Here we identify splenic 15-PGDH, and specifically 15-PGDH-expressing macrophages, megakaryocytes, and
mast cells, as regulators of EMH and propose that targeting splenic 15-PGDH prior to transplant will enhance homing and regeneration, resulting in improved clinical outcomes.

Results

The spleen is critical for PGDHi-mediated hematopoietic regeneration

To determine if the spleen responds to 15-PGDH inhibition, we examined 15-PGDH expression levels in splenic tissue. Splenic 15-PGDH expression was substantially elevated versus that of BM (Figure 1A). Immunohistochemical staining for 15-PGDH also revealed a striking difference in the abundance of 15-PGDH+ cells (Figure 1B). While the BM displayed relatively rare 15-PGDH+ cells, which comprised smaller hematopoietic cells and megakaryocytes, splenic 15-PGDH+ cells were highly numerous, particularly within the red pulp (Supplemental Figure 1). Consistent with these findings, 15-PGDH enzymatic activity was significantly higher in splenic as compared to BM cell lysates (Figure 1C), demonstrating that the abundant 15-PGDH is enzymatically active. Together these results suggested that the spleen may be more sensitive than the marrow to pharmacologic 15-PGDH targeting.

Having established that 15-PGDH is expressed much more highly in the spleen than the marrow, we next sought to determine whether the spleen is required for the hematopoietic protective effects of 15-PGDH inhibition (PGDHi; (14)). To test this, we compared short-term hematologic recovery from transplant in splenectomized versus intact mice. Although vehicle-treated splenectomized mice recovered blood counts slightly faster than intact controls, as has been reported (16, 17), splenectomy markedly attenuated the impact of PGDHi on neutrophil recovery and abrogated the impact of PGDHi on platelet recovery (Figure 1D and Supplemental Figure 2). Importantly, PGDHi-treated mice with spleens reached absolute neutrophil counts of 935 by day 12, as compared to 456 in splenectomized counterparts.
Splenectomized mice also failed to show a PGDHi-dependent acceleration of total white blood cell recovery, suggesting that myeloid to lymphoid lineage skewing was not occurring. In addition, PGDHi did not enhance donor-derived HSPC numbers in the BM of splenectomized mice at day 20 (Figure 1E and Supplemental Figure 3). These data therefore establish that the spleen is required for PGDHi-mediated hematologic recovery.

**PGDHi induces splenic extramedullary hematopoiesis**

To determine if an increase in splenic EMH may underlie PGDHi-mediated hematopoietic protection post-transplant, and thus explain why splenectomized mice do not respond to PGDHi, we characterized the spleens of healthy mice treated for 5 days with PGDHi (Figure 2A). PGDHi-treated mice showed significant increases in total splenic cellularity and in splenic HSPCs (Figure 2B), suggesting that at homeostasis, 15-PGDH negatively regulates hematopoiesis in the spleen. PGDHi also increases BM HSPCs at homeostasis (14), however PGDHi did not significantly increase circulating HSPCs (Supplemental Figure 4), therefore it is unlikely that HSPC mobilization from the BM to the spleen accounts for this effect.

PGE2 signals via prostaglandin receptors EP1-4 (18). Analysis of EP1-4 expression in splenic CD45+ cells revealed a significant predominance in the expression of the gene encoding EP4 relative to EP1, 2, and 3 (Figure 2C). To determine if PGE2 signaling via EP4 may underlie the PGDHi-induced EMH, we treated mice with the EP4 specific agonist, Rivenprost (19) (Figure 2D). Although EP4 agonism was sufficient to increase splenic cellularity, it failed to significantly expand splenic HSPCs (Figure 2E). These data therefore indicate that PGDHi mediates splenic EMH in part via the actions of PGE2-EP4 signaling, but do not rule out involvement of EP1-3 and may indicate that additional pathways, outside of EP signaling, may be involved in PGDHi-mediated regeneration.
**PGDHi expands functional HSPCs in the spleen**

To test whether splenic EMH corresponded to an increase in functional HSPCs in the spleen of PGDHi-treated mice, we transplanted splenocytes from PGDHi-treated donors into lethally irradiated recipients (Figure 3A). A limiting cell dose of 2e6 splenocytes was chosen to assess both survival and hematologic recovery. 47% of mice that received control splenocytes succumbed to hematopoietic failure (Figure 3B) evidenced by pallor, hypothermia, and lethargy (not shown). In contrast, splenocytes derived from PGDHi-treated donors conferred 80% survival. To assess hematologic recovery, surviving mice were sacrificed 22 days post-transplant. Recipients of splenocytes from PGDHi donors showed marked increases in peripheral blood neutrophils, platelets, and a trend towards increased red blood cells (Figure 3C). Although the BM remained hypocellular, PGDHi donor splenocytes were associated with significantly increased engraftment of the BM in total and the lineage- c-Kit+ immature compartment specifically (Figure 3D). To evaluate the impact of PGDHi on the long-term BM engraftment capacity of splenic HSPCs, recipient mice were also analyzed 70 days post-transplant. At this time point, mice were no longer pancytopenic, although they did exhibit persistent thrombocytopenia, which was less severe in recipients of PGDHi donor cells (Supplemental Figure 5A). Moreover, mice that received splenocytes from PGDHi-treated donors maintained an increase in BM cellularity, and further displayed a significant increase in the LSK CD48- CD150- marked short-term HSC (ST-HSC) population but did not exhibit differences in phenotypic long-term (LT-HSC) numbers (Supplemental Figure 5B). Together these data demonstrate that PGDHi enhances the hematopoietic capacity of the spleen to increase cellular proliferation, and expands a population of functionally active spleen-resident HSPCs.
Having established that PGDHi elicits splenic EMH, we next questioned whether drug treatment acted specifically on splenic HSPCs with short-term or lineage-biased repopulation activity. To address this, we competitively transplanted splenocytes from PGDHi- and Veh-treated donors with competitor whole BM cells and quantified peripheral blood chimerism 3-15 weeks post-transplant (Figure 3E). PGDHi conferred a repopulation advantage to transplanted splenocytes over the course of the transplant (Figure 3F). Specifically, splenocytes from PGDHi-treated donors gave rise to increased myeloid lineage cells 3 weeks post-transplant and subsequently increased lymphoid cells 5-9 weeks post-transplant, thus demonstrating that PGDHi-induced splenic EMH occurs via actions on HSPCs with multilineage repopulating activity.

Recipient PGDHi preconditioning enhances homing to the BM and splenic niches

Much like the BM, splenic hematopoiesis is regulated through the local tissue microenvironment (9). As PGDHi elicited splenic EMH in healthy mice, we next sought to test the therapeutic relevance of these findings and determine if pre-transplant PGDHi would increase splenic homing (Figure 4A). Recipient mice treated with PGDHi prior to transplant demonstrated a 1.5-fold increase in the frequency of donor cells present in the spleen 16 hours post-transplant (Figure 4B). Pre-transplant PGDHi also increased the homing of transplanted cells to the BM (Figure 4C), suggesting that 15-PGDH inhibition enhances the capacity of both the splenic and the BM microenvironment to recruit and support engrafting cells.

PGDHi elicits a pro-hematopoietic gene expression signature in the spleen

We next sought to identify whether these PGDHi-mediated effects were associated with a pro-hematopoietic gene expression signature in the spleen and BM. As 15-PGDH expression
localized to the splenic red pulp, we analyzed the expression of a number of hematopoietic niche-related genes (20-22) (Table 1) in lymphoid-depleted BM and splenic cells following 5 days of vehicle or PGDHi treatment. Consistent with our findings that PGDHi induces splenic EMH and promotes homing to the splenic and BM niches, we found that a number of factors were modestly induced including the niche retentive factors Spp1 and Vcam1 (10, 23), and the quiescence-promoting factor Kitl (24) (Figure 5A-B). PGDHi elicited moderate induction of the Ackr1 gene, which has been implicated in maintaining hematopoietic quiescence via the macrophage niche (25), specifically in the spleen (Supplemental Figure 6). The sum of the individual gene expression changes across the panel of hematopoietic niche-associated factors revealed a significant increase in both organs, however, suggesting that PGDHi induces a pro-niche response that facilitates post HST engraftment.

15-PGDH is highly enriched in splenic and BM mast cells, megakaryocytes, and macrophages

Given the functional significance of splenic 15-PGDH, we sought to identify the cellular sources of 15-PGDH activity in murine spleen. Immunohistochemical 15-PGDH staining principally identified hematopoietic cell types, including megakaryocytes; whereas, splenic stroma revealed very low 15-PGDH activity (data not shown). Isolation of bulk CD45+ hematopoietic cells showed no enrichment of 15-PGDH enzymatic activity per milligram protein compared to total unfractionated splenocytes (Figure 6A). To determine whether immature hematopoietic cells are 15-PGDH+, and thus direct targets of PGDHi, we compared hematopoietic lineage negative and lineage positive cells. 15-PGDH activity per milligram protein was very low in the immature, as compared to the mature cell fraction, suggesting that 15-PGDH localizes to a subset of mature cells. Analysis of myeloid cells by CD11b fractionation demonstrated relative enrichment (Supplemental Figure 7), thus we reasoned that the major
cellular sources of 15-PGDH include a myeloid cell type. As prostanoid signaling is known to regulate macrophages (MΦ), megakaryocytes (MK), and mast cells (MC), we measured activity specifically within these fractions. F4/80+ MΦs accounted for the highest level of enzyme activity per milligram protein, but significant enrichment was also measured in CD61+ MKs, and FcεR1a+ MCs. Among these cell types, F4/80+ cells are the most numerous in the spleen, accounting for 19.3% of nucleated splenocytes (Figure 6B). In contrast, CD61+ and FcεR1a+ cells represented 7.6% and 0.3% of nucleated splenocytes, respectively. As a reference, CD3+ cells represented 28.2% of cells analyzed (data not shown). Notably, 15-PGDH activity also localized to CD61+, FcεR1a+, and F4/80+ cells in the BM (Figure 6C), though these levels were much lower than those of the corresponding splenic populations. Among 15-PGDH+ cell types, F4/80+ cells were also the most numerous in the BM (Figure 6D). These data therefore implicate splenic MΦs as the predominant cellular targets of PGDH treatment in hematopoietic tissue.

15-PGDH localization and enzymatic activity is conserved in human BM

To determine if 15-PGDH expression patterns are conserved between murine and human hematopoietic tissue, we evaluated healthy human biopsies and aspirates. 15-PGDH+ marrow cells were readily detectable in all human biopsies examined (Figure 7A). Positive cells varied in size and morphology, and included pyramidal, elongated, and round cells. To identify the cellular localization of 15-PGDH activity, we separated cells from human BM aspirates on the basis of surface marker expression. Relative to the activity of total BM, FcεR1a+ MCs demonstrated 115-fold higher levels of specific 15-PGDH activity (Figure 7B). CD14+ MΦs and CD61+ MK-lineage cells also demonstrated enzyme activity enrichment, though to lesser degrees than FcεR1a+ cells. These results establish that FcεR1a+ MCs, CD61+ MKs, and
CD14+ MΦs are robust sources of 15-PGDH activity in human marrow, and thus may comprise a novel and therapeutically-targetable human HSC niche.

Discussion

Previously, we established that 15-PGDH regulates hematopoietic, colonic epithelial, and hepatic tissue regeneration (13-15). Pharmacologic 15-PGDH inhibition or loss of *Hpgd* expression (that encodes 15-PGDH) elevated BM prostaglandin E2, D2 and F2a levels, increased peripheral neutrophils, and expanded the BM HSPC compartment. PGDHi also enhanced the progenitor activity, homing, and reconstituting ability of murine BM, human BM, and umbilical cord blood. PGDHi induced the expression of niche factors in the BM. However, because splenic colony forming units and splenic HSPCs were also increased, we hypothesized that splenic 15-PGDH also negatively regulates hematopoietic regeneration. Here, we demonstrate robust 15-PGDH expression in splenic red pulp, which localizes to MΦs, MKs, and MCs. Our observation that the spleen is required for PGDHi responses post-transplant, advances current understanding of splenic EMH and identifies potential therapeutic targets within the splenic HSPC niche.

Prostaglandin E2 is an arachidonic acid derivative capable of increasing HSPC numbers in vivo and in vitro (26-28). Although PGE2 can be produced by a multitude of cells types, osteoblasts, endothelial cells, and monocyte-macrophage lineage cells have been most extensively characterized in the HSPC microenvironment (reviewed in (29)). HSPCs and non-hematopoietic microenvironmental cell types express PGE2 receptors (30), and agonism of EP2 and EP4 receptors on HSPCs activates Wnt signaling and increases the expression of anti-apoptotic and pro-proliferative gene programs (31). PGE2 stimulation also increases HSPC CXCR4 expression (32), thus enhancing homing capacity. Recently, a role for MΦ-derived
PGE2 in facilitating erythropoietin-induced erythropoiesis was reported by Chen et al. (33). Clinical trials have evaluated the ex vivo stimulation of human cord blood with the long-acting PGE2 analog dimethyl-PGE2 (dmPGE2) as a strategy to enhance engraftment (34). Ex vivo stimulation avoids the potential for off-target dmPGE2-induced toxicity, however, our data together with the radioprotective and erythropoiesis-promoting effects of PGE2 (26, 27, 33), demonstrate the potential for additional benefit from strategies to elevate tissue PGE2 levels in transplant recipients. Future studies to evaluate dmPGE2 ex vivo graft stimulation combined with pre-transplant PGDHi recipient conditioning are therefore warranted.

In the adult, hematopoiesis takes place primarily in the BM where HSPCs are regulated by perivascular stromal cells, endothelial cells, MΦs, and MKs (35-39). The red pulp of the spleen serves as an alternative HSPC microenvironment when the BM is dysfunctional, however (reviewed in (40)), and provides myelopoiesis and erythropoiesis in response to infection (41), inflammation (42), and physical and psychological stress (43, 44). Rare HSPCs are found in murine spleen under homeostatic conditions (9), however, and recent reports demonstrate human splenic EMH in the absence of disease (45). Here we establish that PGDHi induces nonpathologic splenic EMH. Splenic endothelial and Tcf21+ stromal cells were recently shown to regulate EMH and particularly myeloerythroid lineage differentiation (9). Our studies do not directly address the impact of PGDHi on spleen stroma, but 15-PGDH activity was very low in splenic CD45- cells, indicating that stromal cells are not likely direct PGDHi targets.

PGDHi likely increases splenic cellularity via PGE2 stimulation of EP4 receptor, as EP4 specific agonism recapitulates this phenotype. EP4 agonism is not sufficient to expand the pool of splenic HSPCs, however, suggesting activation of additional EP receptors is required for the induction of splenic EMH by PGDHi. Moreover, PGDHi potentiates splenic homing of transplanted cells. As the spleen is associated with delayed engraftment in some transplant patients (5), our data suggest that PGDHi may provide an alternative to splenectomy or splenic
irradiation. Whether PGDHi improves hematopoietic function in other pathophysiologic states that involve splenic EMH, such as infection or blood loss, is an intriguing question.

BM MKs enforce HSC quiescence via CXCL4 and TGFβ but take on an FGF1-dependent HSC activating role upon hematologic stress (38, 39). Similarly, MΦs maintain quiescence and niche retention at steady-state in part through activities of the atypical chemokine receptor 1 (Ackr1; (25)), and VCAM1 ((10) and reviewed in (46)), but exacerbate inflammation and regulate HSPC differentiation in pathologic conditions (47). Our finding that splenic MKs and MΦs express high levels of enzymatically-active 15-PGDH suggests that these cell types participate in the PGDHi-dependent regulation of splenic EMH. PGE2 limits inflammation in some contexts (48), and irradiation potentiates the inflammatory state of MΦs (49), thus it is possible that PGDHi attenuates MΦ activation to preserve splenic niche function. Additionally, PGE2 inhibits TGFβ signaling (50), therefore, PGDHi treatment may modulate the role of splenic MKs from promoting HSC quiescence to activation. Our work also implicates MCs as components of the splenic EMH microenvironment. MCs are rich in histamine- and leukotriene-containing granules however, and thus are poised to rapidly regulate the local tissue microenvironment. Moreover, leukotriene B4 has been hypothesized to promote HSPC differentiation at the expense of self-renewal (29), and PGE2 suppresses MC degranulation in anaphylaxis (51). Increased splenic myelopoiesis and thrombopoiesis have also been observed in MC deficient mice (52). Future studies to evaluate the impact of PGDHi specifically on splenic MCs, MKs, and MΦs are warranted.

In conclusion, 15-PGDH is highly expressed and enzymatically-active in the murine spleen. Pre-transplant PGDHi induces a pro-niche gene signature in the splenic and BM microenvironments and induces splenic EMH, which translates to an increase in the homing of transplanted cells to the spleen. We find that the spleen is required for PGDHi-mediated leukocyte and platelet reconstitution and BM HSPC engraftment. This likely owes to a network
of 15-PGDH+ macrophages, megakaryocytes, and rare mast cells in the spleen. Therefore, our
work identifies a novel pharmacologic strategy and the corresponding cellular targets that
regulate extramedullary hematopoiesis. Small molecule 15-PGDH inhibition represents a novel
therapeutic strategy to utilize the splenic microenvironment post-transplant and likely in other
disease states where rapid hematopoietic regeneration is needed.

Methods

Reagents: 15-PGDH inhibitors (+)SW033291 and (+)SW209415 were previously described (13, 14), and provided by Dr. Sanford Markowitz. (+)SW033291 was prepared in a vehicle of 10% ethanol, 5% Cremophor EL, 85% dextrose-5 water, at 125ug/200ul for use at 5mg/kg for a 25g mouse, and administered by intraperitoneal (I.P.) injection, twice per day, 6-8 hours apart. (+)SW209415 was prepared as previously described (13), and administered at 2.5mg/kg I.P., twice per day. Rivenprost (Cayman Chemical) was prepared in a vehicle of PBS for use at 30ug/kg and administered by I.P. injection, twice per day, 6-8 hours apart. Carboxyfluorescein succinimidyl ester (CFSE) Cell Trace was purchased from Invitrogen.

Animals: Steady-state and transplantation analyses were performed on 8wk old female C57BL/6J mice obtained from Jackson Laboratories. B6.SJL-Ptprca Pepcb/BoyJ and splenectomized C57BL/6 mice were obtained from Jackson Laboratories. All animals were observed daily for signs of illness. Mice were housed in standard microisolator cages and maintained on a defined, irradiated diet and autoclaved water.

Western blotting: Cells were lysed using RIPA lysis buffer containing protease inhibitors. Lysates were centrifuged 10,000 rpm for 10 minutes at 4C. Protein concentrations were determined by BCA assay. Proteins were separated using 4-12% SDS-PAGE gels, then
transferred to PVDF membranes, and probed with antibodies recognizing murine 15-PGDH (kindly provided by Dr. Sanford Markowitz), and β–actin (Sigma, A5441).

**Histological and immunohistochemical analysis:** Animals were harvested via CO2 inhalation followed by cervical dislocation. Whole spleens or tibial bone marrow plugs from mice, and bone marrow biopsies from human donors were fixed in 10% neutral buffered formalin. Samples were transferred to PBS and shipped to HistoWiz where they were embedded in paraffin, and sectioned at 4μm. Immunohistochemistry was performed according to Histowiz protocols ([https://home.histowiz.com/faq/](https://home.histowiz.com/faq/)). Histowiz defines their standard methods as the use of a Bond Rx autostainer (Leica Biosystems) with enzyme treatment using standard protocols, and detection via Bond Polymer Refine Detection (Leica Biosystems) according to manufacturer’s protocol. Anti-15-PGDH staining was performed using a commercially available antibody (Abcam, EPR14332-19, catalog number ab187161). Whole slide scanning (40x) was performed on an Aperio AT2 (Leica Biosystems).

**Measurement of 15-PGDH enzymatic activity:** Splenic lysates were prepared using the Precellys 24 homogenizer, in a lysis buffer containing 50mM Tris HCl, 0.1mM DTT, and 0.1mM EDTA. Bone marrow was flushed, pelleted, and lysed using the same buffer, with sonication. Enzymatic activity was measured by following the transfer of tritium from a tritiated PGE2 substrate to glutamate by coupling 15-PGDH to glutamate dehydrogenase (53). Activity was expressed as counts per minute, per mg total protein assayed.

**Bone marrow transplantation:** Mice were exposed to 10Gy total body irradiation from a cesium source, followed immediately by administration of PGDHi or vehicle control. 16-18hrs later, mice received 1e6 whole bone marrow cells by retroorbital injection, followed immediately by a second I.P. administration of PGDHi or vehicle control. Recipients continued to receive twice daily I.P. injections of PGDHi or vehicle.
Complete blood count analysis: Peripheral blood was collected into Microtainer EDTA tubes (Becton-Dickinson) by submandibular cheek puncture. Blood counts were analyzed using a Hemavet 950 FS hematology analyzer.

Quantification of HSPCs and splenic cell types: Bone marrow cells were obtained by flushing hindlimb bones and splenocytes were obtained by mincing spleens. Cellularity was measured following red blood cell lysis. Cells were stained with antibodies against CD45R/B220 (RA3-6B2), CD11b (M1/70), CD3e (500A2), Ly-6G and Ly6C (RB6-8C5), TER-119 (TER-119), Ly-6A/E (D7), CD117 (2B8), F4/80 (Cl:A3-1), CD61 (2C9.G2), Fcer1 alpha (MAR-1), CD45.1 (A20), and CD45.2 (104; all obtained from BioLegend with the exception of anti-F4/80, which was obtained from Bio-Rad) and data was acquired on an LSRII flow cytometer (BD Biosciences). Analysis was performed on FlowJo software (TreeStar).

Cell separation: Single cell suspensions were generated from spleen and marrows. Cells were isolated by surface marker expression using Miltenyi microbead kits and LS column separation according to manufacturer’s instructions. 15-PGDH enzymatic activity was measured in cell fractions, or in unfractionated splenocytes or marrow cells, as described above and previously reported (14).

RNA extraction and quantitative PCR: CD45+ splenocytes or CD3e- and B220-depleted bone marrow cells and splenocytes were isolated, as described above. Cells were lysed and RNA extracted using the RNeasy MiniKit (QIAGEN) with on-column DNase treatment, according to the manufacturer’s protocol. cDNA was synthesized using the PrimeScript RT Reagent Kit (Takara) following manufacturer’s instructions. Real time PCR measurement was performed in a 20μl reaction containing 1μl cDNA template and a 1:20 dilution of primer/probe with 1X Accuris Taq DNA polymerase. Samples were run on a CFX96 optical module (Bio-Rad). Thermal cycling conditions were 95C for 3 minutes, followed by 50 cycles of 95C for 15 seconds and 60C for 1 minute. Murine probe/primer sets for all genes assayed were obtained from Life
Technologies and were as follows: \textit{B2m} Mm00437762\_m1, \textit{Ptger1} Mm00443098\_g1, \textit{Ptger2} Mm00436051\_m1, \textit{Ptger3} Mm01316856\_m1, \textit{Ptger4} Mm00436053\_m1, \textit{Actb} Mm02619580\_g1, \textit{Vcam1} Mm01320970\_m1, \textit{Crem} Mm04336053\_g1, \textit{Spp1} Mm00436767\_m1, \textit{Jag1} Mm00496902\_m1, \textit{Kitl} Mm00442972\_m1, \textit{Cxcr4} Mm01996749\_s1, \textit{Acrk1} Mm00515642\_g1, \textit{Gata1} Mm01352636\_m1, \textit{Pf4} Mm00451315\_g1, \textit{Fgf1} Mm00438906\_m1, and \textit{Cxcl12} Mm00445553\_m1. For each reverse transcription reaction, Cq values were determined as the average values obtained from three independent real-time PCR reactions.

**Splenocyte transplantation:** Donor mice were treated for five days with PGDHi or vehicle control, twice daily, by I.P. injection. Two hours following the ninth administration, mice were sacrificed and spleens were dissected and a single cell suspension was generated. For noncompetitive splenocyte transplants, recipient mice were conditioned with 10Gy irradiation 20hrs prior to the transplantation of 2e6 splenocytes by retroorbital injection. For competitive splenocyte transplants, recipient mice were conditioned as described above, and received 5e6 splenocytes from mice treated as described above, plus 5e5 BM cells from untreated CD45.1-expressing (B6.SJL-\textit{Ptprca} Pepcb/BoyJ) mice.

**Bone marrow homing analysis:** Bone marrow was labeled with 5μM CellTrace CFSE and 10e6 cells were transplanted into recipient mice that had been treated for 5 days with PGDHi or vehicle control, and conditioned with 10Gy total body irradiation 12 hours prior to transplant. 16 hours post-transplant, mice were sacrificed and CFSE+ cells were quantified in the spleen and bone marrow flow cytometrically.

**Statistics:** All values were tabulated graphically with error bars corresponding to standard error of the means. Analysis was performed using GraphPad Prism software. Unpaired two-tailed Student’s t-test was used to compare groups, unless otherwise noted. For peripheral blood recovery kinetic analysis, 2-way ANOVA was used to test the effect of drug treatment. P<0.05 was considered statistically significant.
**Study approval:** Animals were housed in the AAALAC accredited facilities of the CWRU School of Medicine. Husbandry and experimental procedures were approved by the Case Western Reserve University Institutional Animal Care and Use Committee (IACUC) in accordance with approved IACUC protocols 2013-0182 and 2019-0065. De-identified adult bone marrow aspirates were obtained from the CWRU Hematopoietic Biorepository with permission from the Institutional Review Board. Human bone marrow aspirates were depleted of red blood cells prior to cell fractionation. The human bone marrow biopsy used for 15-PGDH immunohistochemical staining was derived from a 30 year old female volunteer in accordance with CWRU Institutional Review Board protocols.

**Author contributions:**

Julianne N.P. Smith: Conception and Design, Collection of Data, Data Interpretation, Manuscript Writing

Dawn M. Dawson: Conception and Design, Data Interpretation

Kelsey F. Christo: Collection of Data

Alvin P. Jogasuria: Collection of Data

Mark J. Cameron: Conception and Design

Monika I. Antczak: Chemical Compound Purification and Quality Control

Joseph M. Ready: Chemical Compound Purification and Quality Control

Stanton L. Gerson: Conception and Design, Data Interpretation

Sanford D. Markowitz: Conception and Design, Data Interpretation, Manuscript Writing

Amar B. Desai: Conception and Design, Data Interpretation, Manuscript Writing, Final Approval of Manuscript

**Acknowledgments**
This work was supported by NIH grants R35 CA197442, K99 HL135740, R01 CA216863, and T32 EB005583, and by the Radiation Resources Core Facility (P30CA043703), the Hematopoietic Biorepository and Cellular Therapy Core Facility (P30CA043703), the Tissue Resources Core Facility (P30CA043703), and the Cytometry & Imaging Microscopy Core Facility of the Case Comprehensive Cancer Center (P30CA043703).

References:


doi:10.1016/j.stemcr.2016.03.006


**Figure 1. The spleen is critical for PGDHi-mediated hematopoietic regeneration.**

A. Representative detection of 15-PGDH at 25kD and β-actin at 42kD in splenocyte and bone marrow (BM) cell lysates. Two independent experiments of N = 2 mice per experiment. 

B. Representative images of 15-PGDH staining (brown) in splenic red pulp (left) and tibial BM core (right). 20X magnification. Three independent experiments of N = 2 mice per experiment.

C. Quantification of 15-PGDH enzymatic activity in spleen and BM, expressed as counts per minute (CPM) per mg total protein, per hour. N = 5 mice. Error bars represent SEM.

D. Peripheral white blood cell (WBC), neutrophil (NE), and platelet (PLT) recovery in intact (top) and splenectomized (bottom) transplant recipients treated with either vehicle (Veh; blue) or 15-PGDH inhibitor (PGDHi; red). N = 12-15 mice/group. Data represent mean ± SEM. 

E. BM cellularity and quantification of lineage− c-Kit+ Sca-1+ (LSK) cells per hindlimb of control and splenectomized recipients 20 days post-transplant, treated with Veh (−) or PGDHi (+), expressed as fold change. N = 11-14 mice per group. Error bars represent SEM. **P < 0.01, ****P <
0.0001. Student’s t-test used for all except peripheral blood recovery, where 2-way ANOVA was used and asterisks denote Vehicle vs. PGDHi over days 7 through 20.
Figure 2. PGDHi induces splenic extramedullary hematopoiesis. A. Schematic depicting 15-PGDH inhibition (PGDHi) in steady-state mice over the course of 5 days (9 injections). B. Quantification of splenic cellularity and lineage c-Kit+ Sca-1+ (LSK) cells per spleen following 5 days Veh- and PGDHi-treatment, expressed as fold change. N = 12-13 mice/group for splenic cellularity and N = 7-8 mice per group for splenic LSK number. Error bars represent SEM. C. EP 1-4 (Ptger1, 2, 3, and 4) expressed as delta Cq (ΔCq) relative to B2m control gene expression levels in CD45+ splenocytes. N = 3 mice. Error bars represent SEM. D. Schematic depicting Rivenprost administration in mice over the course of 5 days (9 doses). E. Quantification of splenic cellularity and LSK numbers following 5 days Veh- and Rivenprost (Riv)-treatment, expressed as fold change. N = 10-11 mice/group. Error bars represent SEM. *P < 0.05, ****P < 0.0001. Student’s t-test used for all except for splenic EP receptor expression, where one-way ANOVA with Tukey’s multiple comparisons test was used. PGE2 signaling diagrams created with BioRender.com.
Figure 3. PGDHi expands functional HSPCs in the spleen. A. Schematic depicting the transplantation of splenocytes from PGDHi- or Vehicle (Veh)-treated donors into irradiated, untreated recipients. B. Overall survival time of mice that received splenocytes from Veh- or PGDHi-treated donors. N = 16 mice/group. Statistical testing by Log-rank (Mantel-Cox) test. C. Quantification of peripheral blood neutrophils (NE), platelets (PLT), and red blood cells (RBCs) in mice that received splenocytes from either Veh- or PGDHi-treated donors, 22 days post-transplant. N = 6-8 mice/group. Error bars represent SEM. D. Quantification of BM cellularity and lineage c-Kit+ (LK) BM cells in recipient mice, 22 days post-transplant, expressed as fold change. N = 6-8 mice/group. Error bars represent SEM. E. Schematic depicting the competitive transplantation of splenocytes from PGDHi- or Veh-treated donors together with BM from untreated CD45.1+ donors into irradiated, untreated recipients. F. Peripheral blood (PB) chimerism at indicated timepoints post-transplant, as measured by the percent CD45.2+ cells in total PB, CD11b+ Myeloid PB, and B220+/CD3e+ Lymphoid PB. N = 9-11 recipients/group.
Data represent mean ± SEM. G. Total BM cell chimerism at 15 weeks post-transplant, as measured by the percent CD45.2+ cells. N = 9-11 recipients/group. Error bars represent SEM. *P < 0.05, **P < 0.01, and ***P = 0.0008. Statistical testing of panels C-D was done by Student’s t-test, except in the case of LK cell fold change, where a Mann-Whitney test was performed. Statistical testing of panel F was done by Student’s t-test of the area under the curve of Veh versus PGDH curves.
Figure 4. Recipient PGDHi preconditioning enhances homing to the BM and splenic niches. A. Schematic depicting the analysis of homing into PGDHi-pretreated recipients. B. Representative flow cytometry plots depicting the detection of CFSE+ cells among total splenocytes isolated 16 hours post-transplantation of pretreated mice. Graph represents fold change in the frequency of CFSE+ splenocytes. N = 11-13 mice/group. Error bars represent SEM. C. Representative flow cytometry plots depicting the detection of CFSE+ cells among total bone marrow (BM) cells isolated 16 hours post-transplant in Veh- and PGDHi-pretreated mice. Graph represents fold change in the frequency of CFSE+ BM cells. N = 11-13 mice/group. Error bars represent SEM. *P < 0.05, ****P < 0.0001. Statistical testing by Student’s t-test.
Figure 5. PGDHi elicits a pro-hematopoietic gene expression signature in the spleen and BM. A. Relative expression of indicated genes in lymphoid-depleted splenocytes from vehicle- (blue) and PGDHi- (red) treated mice, normalized to Actb (left). Fold change in the expression of all hematopoietic niche-related genes, listed in panel A (right). N = 3 mice/group. Error bars represent SEM. B. Relative expression of indicated genes in lymphoid-depleted bone marrow (BM) cells from vehicle- (blue) and PGDHi- (red) treated mice, normalized to Actb (left). Fold change in the expression of all hematopoietic niche-related genes, listed in panel A (right). N = 3 mice/group. Error bars represent SEM. *P = 0.02, **P < 0.005, ***P = 0.0001. Statistical testing by Student’s t-test.
Figure 6. 15-PGDH activity is highly enriched in splenic and marrow mast cells, megakaryocytes, and macrophages. A. Quantification of 15-PGDH enzymatic activity in total unfractionated spleen and in splenic CD45, hematopoietic Lineage (Lin), F4/80, CD61, and FcεRIα−/+ fractions, respectively, expressed as CPM per mg total protein, per hour. Filled symbols indicate each marker’s negative population. N = 3-7 mice/cell population. Error bars represent SEM. B. Quantification of the frequency of F4/80+, CD61+, and FcεRIα+ cells in the murine spleen. N = 3 mice. Error bars represent SEM. C. Quantification of 15-PGDH enzymatic activity in total unfractionated bone marrow (BM) and in BM CD45, F4/80, CD61, and FcεRIα−/+ fractions, respectively, expressed as counts per minute (CPM) per mg total protein, per hour. Filled symbols indicate each marker’s negative population. N = 3-7 mice/cell population. Error bars represent SEM. D. Quantification of the frequency of F4/80+, CD61+, and FcεRIα+ cells in the murine BM. N = 3 mice. Error bars represent SEM.
Figure 7. 15-PGDH localization and enzymatic activity is conserved in human BM. A. Representative image of 15-PGDH staining (brown) in a human bone marrow (BM) biopsy. 40X magnification. Six independent experiments of N = 1 marrow donor per experiment. B. Quantification of 15-PGDH enzymatic activity in total (unfractionated) human BM as compared to CD61, Fcεr1a, and CD14-/- fractions, expressed as CPM per mg total protein, per hour. Open symbols indicate each marker’s negative population. N = 3-5 donors. Error bars represent SEM.
Table 1. Hematopoietic niche-related genes assayed.

<table>
<thead>
<tr>
<th>Gene symbol</th>
<th>Gene name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vcam1</td>
<td>Vascular cell adhesion molecule 1</td>
</tr>
<tr>
<td>Crem</td>
<td>cAMP responsive element modulator</td>
</tr>
<tr>
<td>Spp1</td>
<td>Osteopontin</td>
</tr>
<tr>
<td>Jag1</td>
<td>Jagged 1</td>
</tr>
<tr>
<td>Kitl</td>
<td>Kit ligand</td>
</tr>
<tr>
<td>Cxcr4</td>
<td>CXCR4</td>
</tr>
<tr>
<td>Ackr1</td>
<td>Atypical chemokine receptor 1 (Duffy blood group)</td>
</tr>
<tr>
<td>Gata1</td>
<td>GATA binding protein 1</td>
</tr>
<tr>
<td>Pf4</td>
<td>Platelet factor 4</td>
</tr>
<tr>
<td>Fgf1</td>
<td>Fibroblast growth factor 1</td>
</tr>
<tr>
<td>Cxcl12</td>
<td>CXCL12</td>
</tr>
</tbody>
</table>